- Motley Fool•6 hours ago
The biotech has updated research suggesting its new clinical-stage drug could slow down Alzheimer's disease progression.
- Investor's Business Daily•20 hours ago
Biogen stock underplayed promising Alzheimer's Disease drug results on investor concern over a patient seizure.
- Barrons.com•21 hours ago
Earlier today, Barron’s weighed in, calling Biogen “a biotech bargain.” But Biogen’s share price ended the day in the red as some investors engaged in profit taking and others reacted (some say overreacted) to questions about safety. Biogen’s initial share price surge helped to lift the bio biotech exchange-traded funds at a clip that dramatically outpaced the broader market. ProShares Ultra Nasdaq Biotech (BIB) rose as much as 4.9% Friday morning, while the iShares Nasdaq Biotechnology ETF (IBB) and the SPDR S&P Biotech (XBI) each climbed more than 2.4% All three ETFs gave up all, or most of those gains by the closing bell.
BIIB : Summary for Biogen Inc. - Yahoo Finance
Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||285.25 x 100|
|Ask||291.19 x 100|
|Day's Range||281.79 - 306.98|
|52 Week Range||223.02 - 333.65|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||16.27|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|